TY - JOUR
T1 - Evaluation of LAT1 Expression in Patients with Lung Cancer and Mediastinal Tumors
T2 - 18F-FBPA PET Study with Immunohistological Comparison
AU - Watabe, Tadashi
AU - Ose, Naoko
AU - Naka, Sadahiro
AU - Fukui, Eriko
AU - Kimura, Toru
AU - Kanou, Takashi
AU - Funaki, Soichiro
AU - Sasaki, Hidetaka
AU - Kamiya, Takashi
AU - Kurimoto, Kenta
AU - Isohashi, Kayako
AU - Tatsumi, Mitsuaki
AU - Shimosegawa, Eku
AU - Kato, Hiroki
AU - Ohgaki, Ryuichi
AU - Kanai, Yoshikatsu
AU - Shintani, Yasushi
N1 - Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - Purpose of the Report L-type amino acid transporter-1 (LAT1) is a tumor-specific transporter expressed in various tumor types, with minimal expression in normal organs. We previously demonstrated 18F-fluoro-borono-phenylalanine (18F-FBPA) as a selective PET probe for LAT1 in a preclinical study. Herein, we evaluated LAT1 expression in preoperative patients with lung or mediastinal tumors using 18F-FBPA PET and immunofluorescence staining. Patients and Methods The study population included patients with histopathological diagnosis (n = 55): primary lung cancers (n = 21), lung metastases (n = 6), mediastinal tumors (n = 15), and benign lesion (n = 13). PET scanning was performed 1 hour after the injection of 18F-FBPA (232 ± 32 MBq). Immunofluorescence staining was performed on the resected tumor sections using LAT1 antibody. LAT1 staining was graded on a 4-grade scale and compared with the SUVmax on 18F-FBPA PET. Results A positive correlation was observed between the SUVmax of 18F-FBPA PET and LAT1 expression by immunofluorescence staining (r = 0.611, P < 0.001). The SUVmax of 18F-FBPA was 3.92 ± 1.46 in grade 3, 3.21 ± 1.82 in grade 2, 2.33 ± 0.93 in grade 1, and 1.50 ± 0.39 in grade 0 of LAT1 expression. Although 18F-FBPA PET showed variable uptake in lung cancers and mediastinal tumors, benign lesions showed significantly lower SUVmax than those in malignant lesions (P < 0.01). Conclusions Uptake on 18F-FBPA PET reflected the expression level of LAT1 in lung and mediastinal tumors. It was suggested that 18F-FBPA PET can be used for the precise characterization of the tumor in pretreatment evaluation.
AB - Purpose of the Report L-type amino acid transporter-1 (LAT1) is a tumor-specific transporter expressed in various tumor types, with minimal expression in normal organs. We previously demonstrated 18F-fluoro-borono-phenylalanine (18F-FBPA) as a selective PET probe for LAT1 in a preclinical study. Herein, we evaluated LAT1 expression in preoperative patients with lung or mediastinal tumors using 18F-FBPA PET and immunofluorescence staining. Patients and Methods The study population included patients with histopathological diagnosis (n = 55): primary lung cancers (n = 21), lung metastases (n = 6), mediastinal tumors (n = 15), and benign lesion (n = 13). PET scanning was performed 1 hour after the injection of 18F-FBPA (232 ± 32 MBq). Immunofluorescence staining was performed on the resected tumor sections using LAT1 antibody. LAT1 staining was graded on a 4-grade scale and compared with the SUVmax on 18F-FBPA PET. Results A positive correlation was observed between the SUVmax of 18F-FBPA PET and LAT1 expression by immunofluorescence staining (r = 0.611, P < 0.001). The SUVmax of 18F-FBPA was 3.92 ± 1.46 in grade 3, 3.21 ± 1.82 in grade 2, 2.33 ± 0.93 in grade 1, and 1.50 ± 0.39 in grade 0 of LAT1 expression. Although 18F-FBPA PET showed variable uptake in lung cancers and mediastinal tumors, benign lesions showed significantly lower SUVmax than those in malignant lesions (P < 0.01). Conclusions Uptake on 18F-FBPA PET reflected the expression level of LAT1 in lung and mediastinal tumors. It was suggested that 18F-FBPA PET can be used for the precise characterization of the tumor in pretreatment evaluation.
KW - F-FBPA
KW - LAT1
KW - lung cancer
KW - mediastinal tumor
KW - PET
UR - https://www.scopus.com/pages/publications/85170187492
UR - https://www.scopus.com/pages/publications/85170187492#tab=citedBy
U2 - 10.1097/RLU.0000000000004816
DO - 10.1097/RLU.0000000000004816
M3 - Article
C2 - 37682600
AN - SCOPUS:85170187492
SN - 0363-9762
VL - 48
SP - 853
EP - 860
JO - Clinical nuclear medicine
JF - Clinical nuclear medicine
IS - 10
ER -